Evidence map›Paper›PMID 26821278›Full record

ArticleMagnetic resonance imaging2016

Prostate MRSI predicts outcome in radical prostatectomy patients.

Kristen L Zakian, William Hatfield, Omer Aras, Kun Cao, Derya Yakar, Debra A Goldman, Chaya S Moskowitz, Amita Shukla-Dave, Yousef Mazaheri Tehrani, Samson Fine and 2 more

Abstract read
In one paragraph

Article in Magnetic resonance imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. SimultaneousFrontiers in oncology · 2018
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Kristen L ZakianMemorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: zakiank@mskcc.org.
William HatfieldMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: wnhat1@student.monash.edu.
Omer ArasMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: araso@mskcc.org.
Kun CaoMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: kun-cao@hotmail.com.
Derya YakarMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: derya.yakar@radboudumc.nl.
Debra A GoldmanMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: goldmand@mskcc.org.
Chaya S MoskowitzMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: moskowc1@mskcc.org.
Amita Shukla-DaveMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: davea@mskcc.org.
Yousef Mazaheri TehraniMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: mazahery@mskcc.org.
Samson FineMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: fines@mskcc.org.
James EasthamMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: easthamj@mskcc.org.
Hedvig HricakMSKCC, 1275 York Avenue, NY, NY, 10065, USA. Electronic address: hricakh@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
IMAGING IN RISK ASSESSMENT OF PROSTATE CANCER PATIENTSR01CA076423 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI HRICAK, HEDVIG · 1999 to 2010
$2.3M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA076423
6 · The paper itself

Abstract

backgroundNew non-invasive methods are needed for sub-stratifying high-risk prostate cancer patients. Magnetic resonance spectroscopic imaging (MRSI) maps metabolites in prostate cancer, providing information on tumor aggressiveness and volume. PURPOSE: To investigate the correlation between MRSI and treatment failure (TF) after radical prostatectomy (RP).

methodsTwo-hundred sixty-two patients who underwent endorectal MRI/MRSI followed by RP at our institution from 2003 to 2007 were studied. MRI stage, number of voxels in the MRSI index lesion (NILV), number of high-grade voxels (NHGV), and number of voxels containing undetectable polyamines (NUPV) were derived. Clinical outcome was followed until August, 2014. Treatment failure was defined as 1) biochemical recurrence (BCR), 2) persistently detectable PSA after RP, or 3) adjuvant therapy initiated in the absence of BCR. MRI/MRSI features and clinical parameters were compared to TF by univariate Cox Proportional Hazards Regression. After backward selection, each MRSI parameter was included in a separate regression model adjusted for NCCN-based clinical risk score (CRS), number of biopsy cores positive (NPC), and MRI stage.

resultsIn univariate analysis, all clinical variables were associated with TF in addition to MRI stage, NILV, NHGV, and NUPV. In multivariate analysis, NILV, NHGV, and NUPV were also significant risk factors for TF (p=0.016, p=0.002, p=0.006, respectively). The association between the number of tumor voxels with undetectable polyamines and the probability of treatment failure has not been previously reported. The number of MRSI cancer voxels correlated with extracapsular extension (ECE) (p<0.0001).

conclusionsMRSI was associated with post-radical prostatectomy treatment failure in models adjusted for the number of positive biopsy cores and clinical risk score. This is the first report that in radical prostatectomy patients MRSI has an association with treatment failure independent of the number of positive biopsy cores. MRSI may help the clinician determine whether patients with high risk disease who undergo RP are candidates for specialized additional treatment.

Indexed as

ProstatectomyAdultAgedHumansMagnetic Resonance SpectroscopyMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessPredictive Value of TestsProstateProstatic NeoplasmsRisk FactorsTreatment OutcomeCholineGleason scoreMRIMRSIProstate cancerSpectroscopy

Identifiers

PMID26821278
PMCPMC4860021
OpenAlexW2250280479

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.